Avsnitt
-
"Growing up in a science-driven environment influenced my trajectory, from my father's chemistry background at Kodak to my own experiences in academia and research."
In part one of our conversation with Michael Paliotti, Regional Sales Director at Millipore Sigma, we explore his journey from a science-driven upbringing to his early career in research and forensics. Michael shares how his father's work as an organic chemist at Kodak influenced his path into science, his academic experiences at the University of Notre Dame and Duquesne University, and his unexpected detour into optometry school before finding his true calling in research.
Michael holds a degree in biology from the University of Notre Dame and a master's degree from Duquesne University. Before joining Millipore Sigma, he honed his skills in academic research at the University of Pittsburgh, forensic science with the Pennsylvania State Police, and biotech startups. -
In this final part of our conversation with Stavros, founder and CEO of TileDB, we explore the challenges and opportunities in transforming data management within the life sciences sector. Stavros discusses how smaller organizations often lag behind in adopting innovative solutions due to lack of awareness and reliance on existing tools, while larger companies like big pharma are more proactive in seeking advanced technologies.
Stavros highlights the importance of behavioral change in technology adoption, emphasizing that companies should focus on their core competencies rather than building infrastructure. He draws parallels with AWS, which revolutionized server management by allowing companies to focus on their products rather than infrastructure. The conversation also touches on the moral obligation of life sciences companies to optimize efficiency, given the impact on human lives. -
Saknas det avsnitt?
-
"We're wasting money. You're wasting money as an organization, like, hundreds of millions of dollars that can save you that money easily. But you have to start reasoning a little bit differently."
In this third part of our conversation with Stavros Papadopoulos, founder and CEO of TileDB, we delve into the company's ambitious vision to revolutionize data management in the life sciences sector. Stavros shares the journey of TileDB from its inception as a highly technical solution to its current position as a potential game-changer in how organizations handle diverse data types. He discusses the challenges of selling innovative solutions to large pharmaceutical companies and the stark contrast in adoption between big pharma and smaller organizations.
Stavros, with his background as a technologist from MIT, details the early days of TileDB, emphasizing the intense focus on technological innovation and performance optimization. He describes the company's evolution from a small team of highly skilled engineers to securing significant funding and attracting major customers in the life sciences sector. Throughout the conversation, Stavros highlights the philosophical aspect of TileDB's mission, stressing its potential impact on accelerating scientific discovery and ultimately saving lives. -
"Serendipity plays a big role, but you need to chase it, man. You need to [chase it] and you need to perform. You need to deliver [on] your end of the deal."
In part two of our conversation with Stavros Papadopoulos, founder of TileDB, we delve into his journey from academia to entrepreneurship. Stavros shares his experiences at MIT and Intel, and the serendipitous events that led to the founding of his company. He details the transition from working on cutting-edge database systems to identifying a market need in the life sciences sector, particularly in handling complex genomic data.
Stavros's background in computer science and his work at the intersection of Intel and MIT uniquely positioned him to tackle the challenges of building a new type of database system. His journey highlights the importance of proactivity, networking, and being prepared for unexpected opportunities. He also shares valuable insights on the realities of starting a database company, including the significant funding requirements and the necessity of continuous learning. -
"If you are capable of acquiring knowledge, of applying the knowledge, and you like it, you can succeed. It doesn't matter what it is."
In this episode of The Biotech Startups Podcast, we delve into Stavros Papadopoulos' transformative journey from Greece to Hong Kong, exploring his experiences as a PhD student at the Hong Kong University of Science and Technology. Stavros shares how a chance encounter on a bus and his professor's last-minute recommendation led him to pursue his doctorate in Hong Kong, a decision that would shape his career and personal life.
Stavros describes Hong Kong as the "best city in the world," highlighting the perfect balance between intense academic rigor and vibrant city life. He explains how the university's unique environment, with students working late into the night and a campus integrated into the natural landscape, fostered both hard work and adventure. Stavros also touches on his research focus, which evolved from spatiotemporal databases to data security and cryptography, and how he learned valuable skills that continue to shape his career to this day. -
"If I'm not building something, then I'm probably not going to be doing it for long. That's the fun part."
In part two of our conversation with Becky Beattie, CEO of LaunchBio, we explore her journey scaling a national nonprofit dedicated to supporting early-stage life science founders. Becky shares how she transitioned from BioLabs to LaunchBio, initially joining what she jokingly calls "a lunch club," and eventually stepping into leadership during the pandemic. She details LaunchBio's evolution from local programming to a national organization connecting biotech entrepreneurs with critical resources and capital.
Becky's background in both science and real estate uniquely positioned her to understand the challenges of biotech startups, particularly around shared lab spaces and ecosystem development. Her leadership at LaunchBio has focused on creating targeted connections between founders and investors while expanding into new markets and launching initiatives for underrepresented entrepreneurs. -
In part one of our conversation with Becky Beattie, CEO of LaunchBio, we trace her unconventional path from rural San Jose pig farmer to biotech ecosystem builder. Becky shares how her early entrepreneurial grit, scientific curiosity, and business acumen converged to shape her career – including surviving a life-altering spinal injury and pioneering shared lab spaces.
Becky holds dual degrees in molecular biology and business from the University of Colorado Boulder. Before leading LaunchBio, she honed her skills in life science sales (SeraCare, Eppendorf), strategic marketing (Comprendia), and real estate innovation (ROC Shared Workspace). -
“I didn’t set out to be an entrepreneur, but when I couldn’t find a company doing what I believed in, I built my own.”
In part two of our conversation with Kate Yen, Founder and CEO of Auron Therapeutics, we explore her journey from leading a novel cancer therapy program at Agios to founding her own biotech company.
Kate shares insights into drug development, clinical trials, and the business of biotech, highlighting the importance of translational biology, strategic partnerships, and lean operations in building a successful biotech startup.
Kate earned her Ph.D. in Biological Chemistry from UCLA, where she also completed her postdoc. Before Auron, she held roles at Merck and as a UCLA professor before joining Agios Pharmaceuticals, where she led the IDH translational research team behind two FDA-approved IDH mutant inhibitors and co-led the discovery of vorasidenib, a promising glioma therapy now in clinical development. -
Part 1 of 2: Our guest today is Kate Yen, Founder and CEO of Auron Therapeutics.
Auron Therapeutics leverages cutting-edge science and AI-powered analysis to develop next-generation cancer therapies by mapping key drivers of tumorigenesis.
Kate earned her Ph.D. in Biological Chemistry from UCLA, where she also completed her postdoc. She held roles at Merck and as a UCLA professor before joining Agios Pharmaceuticals, where she led the IDH translational research team behind two FDA-approved IDH mutant inhibitors and co-led the discovery of vorasidenib, a promising glioma therapy now in clinical development.
With deep expertise in preclinical and clinical research, a proven track record in advancing breakthrough therapies, and a passion for oncology, Kate’s journey and insights are invaluable. -
Part 2 of 2: Our guest today is Oguzhan Atay, Co-founder & CEO of BillionToOne. BillionToOne is a precision diagnostics company that quantifies biology to create powerful molecular diagnostics. They work to improve disease detection by counting molecules with their proprietary molecular counting platform. They place patients at the forefront of everything they do and are currently applying their proprietary technology to non-invasive prenatal screening and liquid biopsy.
Oguzhan holds a Ph.D. from Stanford in Systems Biology, where he implemented machine learning algorithms and mathematical models to solve specific problems in cellular biology and developed a data-driven mathematical framework to simplify the analysis of complex biological networks. He also has a degree in Molecular Biology from Princeton, as well as minors in Computer Science, Physics, and Applied Mathematics.
Oguzhan not only combines deep technical expertise with visionary leadership, but he also has an incredibly inspirational immigrant journey, which makes this series a must-listen for first-time founders, scientists, and industry leaders alike. -
Part 1 of 2: Our guest today is Oguzhan Atay, Co-founder & CEO of BillionToOne. BillionToOne is a precision diagnostics company that quantifies biology to create powerful molecular diagnostics. They work to improve disease detection by counting molecules with their proprietary molecular counting platform. They place patients at the forefront of everything they do and are currently applying their proprietary technology to non-invasive prenatal screening and liquid biopsy.
Oguzhan holds a Ph.D. from Stanford in Systems Biology, where he implemented machine learning algorithms and mathematical models to solve specific problems in cellular biology and developed a data-driven mathematical framework to simplify the analysis of complex biological networks. He also has a degree in Molecular Biology from Princeton, as well as minors in Computer Science, Physics, and Applied Mathematics. -
Part 2 of 2: Our guest today is Parag Shah, CEO and Founding Managing Director of K2 HealthVentures. K2 HealthVentures is an alternative investment firm that provides flexible, long-term financing solutions to innovative private and public companies in the life sciences and healthcare industries. Committed to making a broader impact, K2 also donates a percentage of its profits to support underserved areas in healthcare.
Before founding K2, Parag was Senior Managing Director & Group Head of the Life Sciences practice at Hercules Capital, where he led the fund’s public offering and managed over $2 billion in investments. His deep expertise in life science and healthcare financing was further shaped through key leadership roles at Comerica, Imperial Bank, and BankBoston.Parag’s academic background includes a Masters in Environmental Policy & Planning and a Bachelors in Molecular Biology from MIT, where he conducted research at the Whitehead Institute.
With 25+ years of experience at the intersection of science and finance, Parag brings invaluable insights for first-time founders, investors, scientists, and industry leaders navigating the complexities of biotech funding. -
Part 1 of 2: Our guest today is Parag Shah, CEO and Founding Managing Director of K2 HealthVentures. K2 HealthVentures is an alternative investment firm that provides flexible, long-term financing solutions to innovative private and public companies in the life sciences and healthcare industries. Committed to making a broader impact, K2 also donates a percentage of its profits to support underserved areas in healthcare.
Before founding K2, Parag was Senior Managing Director & Group Head of the Life Sciences practice at Hercules Capital, where he led the fund’s public offering and managed over $2 billion in investments. His deep expertise in life science and healthcare financing was further shaped through key leadership roles at Comerica, Imperial Bank, and BankBoston.Parag’s academic background includes a Masters in Environmental Policy & Planning and a Bachelors in Molecular Biology from MIT, where he conducted research at the Whitehead Institute.
With 25+ years of experience at the intersection of science and finance, Parag brings invaluable insights for first-time founders, investors, scientists, and industry leaders navigating the complexities of biotech funding. -
Part 2 of 2: My guest today is Jason C. Foster, CEO and Executive Director of Ori Biotech. Ori is revolutionizing Cell and Gene Therapy manufacturing through the development of its proprietary platform, IRO®. By automating and standardizing Cell and Gene Therapy manufacturing, Ori and IRO® offer scientists the tools they need to streamline development and support widespread patient access to life-saving treatments.
Jason's experience prior to Ori includes more than 20 years of life science leadership in operations, sales, marketing, technology, and investing, during which he developed deep expertise in commercial strategy and a thorough understanding of healthcare markets across the UK, US, and EU. -
Part 1 of 2: My guest today is Jason C. Foster, CEO and Executive Director of Ori Biotech. Ori is revolutionizing Cell and Gene Therapy manufacturing through the development of its proprietary platform, IRO®. By automating and standardizing Cell and Gene Therapy manufacturing, Ori and IRO® offer scientists the tools they need to streamline development and support widespread patient access to life-saving treatments.
Jason's experience prior to Ori includes more than 20 years of life science leadership in operations, sales, marketing, technology, and investing, during which he developed deep expertise in commercial strategy and a thorough understanding of healthcare markets across the UK, US, and EU. -
Part 4 of 4: My guest today is Rafael Rosengarten, CEO and Co-Founder of Genialis, the RNA biomarker company. Genialis is reimagining biomarkers for every target, drug, and patient using a combination of precision oncology, RNA, and AI.
Rafael, a biomedical research veteran, combines academic excellence with industry innovation. A Dartmouth graduate with a Yale doctorate, he conducted postdoctoral research at Lawrence Berkeley National Laboratory, where he co-invented the j5 DNA assembly tool. As co-founder of the Alliance for AI in Healthcare, he advocates for responsible AI integration in medicine, drawing from his extensive background in evolution, immunology, bioengineering, and genetics. -
Part 3 of 4: My guest today is Rafael Rosengarten, CEO and Co-Founder of Genialis, the RNA biomarker company. Genialis is reimagining biomarkers for every target, drug, and patient using a combination of precision oncology, RNA, and AI.
Rafael, a biomedical research veteran, combines academic excellence with industry innovation. A Dartmouth graduate with a Yale doctorate, he conducted postdoctoral research at Lawrence Berkeley National Laboratory, where he co-invented the j5 DNA assembly tool. As co-founder of the Alliance for AI in Healthcare, he advocates for responsible AI integration in medicine, drawing from his extensive background in evolution, immunology, bioengineering, and genetics. -
Part 2 of 4: My guest today is Rafael Rosengarten, CEO and Co-Founder of Genialis, the RNA biomarker company. Genialis is reimagining biomarkers for every target, drug, and patient using a combination of precision oncology, RNA, and AI.
Rafael, a biomedical research veteran, combines academic excellence with industry innovation. A Dartmouth graduate with a Yale doctorate, he conducted postdoctoral research at Lawrence Berkeley National Laboratory, where he co-invented the j5 DNA assembly tool. As co-founder of the Alliance for AI in Healthcare, he advocates for responsible AI integration in medicine, drawing from his extensive background in evolution, immunology, bioengineering, and genetics. -
Part 1 of 4: My guest today is Rafael Rosengarten, CEO and Co-Founder of Genialis, the RNA biomarker company. Genialis is reimagining biomarkers for every target, drug, and patient using a combination of precision oncology, RNA, and AI.
Rafael, a biomedical research veteran, combines academic excellence with industry innovation. A Dartmouth graduate with a Yale doctorate, he conducted postdoctoral research at Lawrence Berkeley National Laboratory, where he co-invented the j5 DNA assembly tool. As co-founder of the Alliance for AI in Healthcare, he advocates for responsible AI integration in medicine, drawing from his extensive background in evolution, immunology, bioengineering, and genetics. -
Part 4 of 4: My guest today is Cyriac Roeding, founder, investor, and CEO of Earli, a company on a mission to transform cancer into a manageable condition. Using innovative gene therapy approaches, Earli’s technology forces cancer cells to produce a synthetic, non-human biomarker—overcoming the limitations of relying on naturally occurring biomarkers that cancer may or may not provide.
- Visa fler
